ES2182104T3 - Piperidinas 1,4-disustituidas como antagonistas muscarinicos. - Google Patents

Piperidinas 1,4-disustituidas como antagonistas muscarinicos.

Info

Publication number
ES2182104T3
ES2182104T3 ES97932321T ES97932321T ES2182104T3 ES 2182104 T3 ES2182104 T3 ES 2182104T3 ES 97932321 T ES97932321 T ES 97932321T ES 97932321 T ES97932321 T ES 97932321T ES 2182104 T3 ES2182104 T3 ES 2182104T3
Authority
ES
Spain
Prior art keywords
rent
piperidins
cyclalquenyl
ach
conr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97932321T
Other languages
English (en)
Inventor
Theodros Asberom
Derek B Lowe
Michael J Green
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp & Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ES2182104T3 publication Critical patent/ES2182104T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE PRESENTAN ANTAGONISTAS MUSCARINICOS DE PIPERIDINAS 1,4 DISUSTITUIDAS DE FORMULA (I) O UNA SAL, ESTER O SOLVATO FARMACEUTICAMENTE ACEPTABLE DE LAS MISMAS, EN LA QUE X ES UN ENLACE, - O -, - S -, - SO 2 -, - CO -, - C(OR 7 ) 2 -, - CH 2 - O -, - O - CH 2 -, - CH=CH -, - CH 2 -, - CH(ALQUILO C 1 - C 6 ), - C(ALQUILO C 1 C SUB,6 ) 2 -, - CONR 17 -, - NR 17 CO -, SO 2 NR 17 - O - NR 17 SO 2 -; R ES CICLOALQUILO C 3 - C 6 , (A), (B), (C), (D), (3), FENILO OPCIONALMENTE S USTITUIDO O PIRIDILO OPCIONALMENTE SUSTITUIDO; R 1 ES H, CN, - CF 3 , ALQUILO, CICLOALQUILO, CICLOALQUENILO, ALQUENILO, - COR 15 , - COO(ALQUILO, ARILO, HETEROARILO, ALQUILA RILO O ALQUILHETEROARILO), ALQUILARILO, ALQUILHETEROARILO O CON(R 13 ) 2 ; R 2 ES CICLOALQUILO, CICLOALQUENILO, T - BUTOXICARBONILO O 4 - PIPERIDINILO OPCIONALMENTE SUSTITUIDO; R 3 Y R 4 SON H, HALO, - CF 3 , ALQUILO, ALCO XI O OH; R 5 Y R 6 SON H, ALQUILO, - CF 3 , ALCOXI, - OH, ALQUILCARBONILO, ALCOXICARBONILO, R 13 CONH -, R 14 OCONH -, R 13 NHCONH - ONH 2 CONR 13 -; R 7 ES H, ALQUILO C 1 - C 6 , ARILO O HETEROARILO; QUE SON UTILES EN EL TRATAMIENTO DE TRASTORNOS COGNOSCITIVOS TALES COMO LA ENFERMEDAD DE ALZHEIMER, ASI COMO COMPOSICIONES FARMACEUTICAS Y PROCEDIMIENTOS PARA SU PREPARACION. TAMBIEN SE PRESENTAN COMBINACIONES DE COMPUESTOS DE FORMULA (I) CAPACES DE AUMENTAR LA LIBERACION DE ACH CON INHIBIDORES DE ACH''ASA.
ES97932321T 1996-07-10 1997-07-08 Piperidinas 1,4-disustituidas como antagonistas muscarinicos. Expired - Lifetime ES2182104T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67861896A 1996-07-10 1996-07-10

Publications (1)

Publication Number Publication Date
ES2182104T3 true ES2182104T3 (es) 2003-03-01

Family

ID=24723553

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97932321T Expired - Lifetime ES2182104T3 (es) 1996-07-10 1997-07-08 Piperidinas 1,4-disustituidas como antagonistas muscarinicos.

Country Status (14)

Country Link
EP (1) EP0912515B1 (es)
JP (1) JP3068206B2 (es)
KR (1) KR20000023599A (es)
AT (1) ATE227708T1 (es)
AU (1) AU728592B2 (es)
CA (1) CA2259655C (es)
DE (1) DE69717109T2 (es)
DK (1) DK0912515T3 (es)
ES (1) ES2182104T3 (es)
HU (1) HUP9904622A3 (es)
IL (1) IL127942A0 (es)
NZ (1) NZ333513A (es)
PT (1) PT912515E (es)
WO (1) WO1998001425A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1600599A (en) * 1998-02-27 1999-09-15 Warner-Lambert Company Heterocyclic substituted aniline calcium channel blockers
PL203117B1 (pl) * 1999-05-04 2009-08-31 Schering Corp Piperydynopiperydynowa pochodna użyteczna jako antagonista CCR5, zawierająca ją kompozycja farmaceutyczna i jej zastosowanie
US6635646B1 (en) 1999-05-04 2003-10-21 Schering Corporation Pegylated interferon alfa-CCR5 antagonist combination HIV therapy
US6387930B1 (en) 1999-05-04 2002-05-14 Schering Corporation Piperidine derivatives useful as CCR5 antagonists
AR033517A1 (es) 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
AU6589801A (en) * 2000-04-28 2001-11-12 F. Hoffmann-La Roche Ag P-(sulfonyl)aryl and heteroaryls
US6640155B2 (en) 2000-08-22 2003-10-28 Lam Research Corporation Chemical mechanical polishing apparatus and methods with central control of polishing pressure applied by polishing head
DE60209736T2 (de) 2001-07-02 2006-11-02 Astrazeneca Ab Piperidinverbindungen, die sich als modulatoren der chemokinrezeptoraktivität eignen
GB0120461D0 (en) 2001-08-22 2001-10-17 Astrazeneca Ab Novel compounds
AR036366A1 (es) * 2001-08-29 2004-09-01 Schering Corp Derivados de piperidina utiles como antagonistas de ccr5, composiciones farmaceuticas, el uso de dichos derivados para la fabricación de un medicamento y un kit
GB0122503D0 (en) 2001-09-18 2001-11-07 Astrazeneca Ab Chemical compounds
PL370799A1 (en) * 2001-12-03 2005-05-30 F.Hoffmann-La Roche Ag Aminotetralin derivatives as muscarinic receptor antagonists
SE0200844D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0200843D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
KR100935615B1 (ko) * 2002-06-14 2010-01-07 토야마 케미칼 컴퍼니 리미티드 뇌기능을 개선하는 의약조성물 및 뇌기능을 개선하기 위한방법
SE0202838D0 (sv) * 2002-09-24 2002-09-24 Astrazeneca Ab Chemical compounds
GB0223223D0 (en) * 2002-10-07 2002-11-13 Novartis Ag Organic compounds
RU2224516C1 (ru) * 2002-10-17 2004-02-27 Государственное учреждение Институт токсикологии Гидрохлорид 1-фенил-1-циклопентил-4-пиперидино-2-бутин-1-ола (пентифин), обладающий м4 холиноблокирующей активностью
SE0300957D0 (sv) 2003-04-01 2003-04-01 Astrazeneca Ab Chemical compounds
EP1805142A4 (en) 2004-09-23 2009-06-10 Reddy Us Therapeutics Inc PYRIDINE-BASED COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING SAME
CA2615650A1 (en) 2005-07-21 2007-01-25 Astrazeneca Ab Novel piperidine derivatives
BRPI0614262A2 (pt) 2005-08-02 2011-03-15 Lexicon Pharmaceuticals Inc aril piridinas e métodos para uso das mesmas

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995004050A1 (en) * 1993-07-28 1995-02-09 Santen Pharmaceutical Co., Ltd. Novel 1,4-di(phenylalkyl)piperazine derivative
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists

Also Published As

Publication number Publication date
NZ333513A (en) 2000-04-28
CA2259655A1 (en) 1998-01-15
CA2259655C (en) 2003-05-13
HUP9904622A3 (en) 2001-07-30
WO1998001425A1 (en) 1998-01-15
JP3068206B2 (ja) 2000-07-24
ATE227708T1 (de) 2002-11-15
IL127942A0 (en) 1999-11-30
PT912515E (pt) 2003-03-31
DE69717109D1 (de) 2002-12-19
JPH11514671A (ja) 1999-12-14
HUP9904622A2 (hu) 2000-06-28
AU3581097A (en) 1998-02-02
EP0912515A1 (en) 1999-05-06
DK0912515T3 (da) 2003-03-10
KR20000023599A (ko) 2000-04-25
DE69717109T2 (de) 2003-04-30
AU728592B2 (en) 2001-01-11
EP0912515B1 (en) 2002-11-13

Similar Documents

Publication Publication Date Title
ATE297381T1 (de) Ether-muskarinantagonisten
KR960701033A (ko) 효능있는 칼슘 길항 및 산화방지 활성을 모두 갖는 화합물, 및 세포보호제로서 그것의 사용방법(compounds having both potent calcium antagonist and antioxidant activity and use there of as cytoprotective agents)
EA200100553A1 (ru) Замещенные бициклические производные, полезные в качестве противораковых агентов
ES2179353T3 (es) Antagonistas muscarinicos.
EA200001146A1 (ru) Производные изотиазола, применимые в качестве противораковых агентов
KR930003912A (ko) 울혈성 심장 마비 치료법
DE69432243D1 (de) 2-Phenyl-3-Aroylbenzothiophene zur Behandlung der menstruellen Symptome
BRPI0408108A (pt) composto, composição farmacêutica, métodos para bloquear em receptor mu, kappa, delta ou uma combinação de receptores dos mesmos em um mamìfero, para tratar ou prevenir obesidade e doenças relacionadas e para suprimir apetite, e, uso de um composto
ATE360630T1 (de) Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors
PL361361A1 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
DE69333143D1 (de) Substituierte chinuclidine als substanz p antagonisten
ES2685923T3 (es) Composición medicinal para mejorar la función cerebral
RU94044436A (ru) Способы подавления атрофии кожи и влагалища
DK0651999T3 (da) Fremgangsmåder til inhibering af livmoderfibrose
DE69132713D1 (de) Benzylidenthiazolidinderivate, ihre Herstellung und ihre Anwendung als Lipidperoxid-Inhibitoren
PL361282A1 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
ATE202343T1 (de) Tricyclische derivate und ihre anwendung als arzneimittel
MX340965B (es) Combinaciones para el tratamiento de enfermedades que involucran la proliferacion celular.
ES2337887T3 (es) Derivados de pirrolidina en calidad de moduladores de prostaglandina.
IL104869A0 (en) Substituted indole,azaindole and tetrahydro-1h-pyrrolo-(2,3-c)pyridine-7-one derivatives,their preparation and pharmaceutical compositions containing them
RU2006124863A (ru) Трициклические производные индолгидроксиэтиламина и их применение при лечении болезни альцгеймера
AR045914A1 (es) Compuesto alcoholico terciario del 8-azoniabiciclo [3.2.1] octano, composicion farmaceutica que lo comprende y su uso para preparar esta ultima
RU2008114048A (ru) Комбинации, включающие ингибитор рецептора сэфр (сосудистого эндотелиального фактора роста) и агент, увеличивающий проницаемость
DE69214587D1 (de) Methanoanthracene als Dopaminantagonisten
RU94045156A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования преждевременного полового созревания